Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
E. Resta (Foggia, Italy), G. Carpagnano (Bari, Italy), C. Pelaia (Catanzaro, Italy), M. D'Amato (Napoli, Italy), N. Crimi (Catania, Italy), N. Scichilone (Palermo, Italy), C. Calabrese (Napoli, Italy), O. Resta (Bari, Italy), G. Scioscia (Foggia, Italy), G. Pelaia (Catanzaro, Italy), M. Foschino Barbaro (Foggia, Italy)
Source: Virtual Congress 2020 – How do different treatment strategies translate into costs
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Resta (Foggia, Italy), G. Carpagnano (Bari, Italy), C. Pelaia (Catanzaro, Italy), M. D'Amato (Napoli, Italy), N. Crimi (Catania, Italy), N. Scichilone (Palermo, Italy), C. Calabrese (Napoli, Italy), O. Resta (Bari, Italy), G. Scioscia (Foggia, Italy), G. Pelaia (Catanzaro, Italy), M. Foschino Barbaro (Foggia, Italy). Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. 4809
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: